ArticleLeukemia2020
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Open access · hybridAbstract readLetterComment
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial.Life (Basel, Switzerland) · 2025Article
- The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.Leukemia · 2023Article
- SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?International journal of molecular sciences · 2023Review
- Recognition of Differentially Expressed Molecular Signatures and Pathways Associated with COVID-19 Poor Prognosis in Glioblastoma Patients.International journal of molecular sciences · 2023Article
- Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.Frontiers in medicine · 2023Article
- Editorial: Immune response to respiratory viruses and respiratory viral infections in susceptible populations.Frontiers in medicine · 2023Article
- Small molecules in the treatment of COVID-19.Signal transduction and targeted therapy · 2022Review
- JAK inhibition as a new treatment strategy for patients with COVID-19.Biochemical pharmacology · 2022Review
- Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.Drug development research · 2022Review
- Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.Pneumonia (Nathan Qld.) · 2021Review
- Perfusion Patterns of Peripheral Pulmonary Lesions in COVID-19 Patients Using Contrast-Enhanced Ultrasound (CEUS): A Case Series.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2021Article
- COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.Cytokine & growth factor reviews · 2021Review
- Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.Biomedicines · 2021Article
- [Antineoplasic drug repurposing in hematology for COVID-19 treatment].Bulletin du cancer · 2021Article
- Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.Leukemia · 2021Observational
Corrections and comments
- Comment on
Authors and funding
13 authors at 3 institutions in 1 country.
Andreas NeubauerDepartment of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany. neubauer@staff.uni-marburg.de.
Thomas WiesmannDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Hospital Giessen and Marburg and Philipps University Marburg, Member of the German Center for Lung Research (DZL), Baldinger Strasse 1, Marburg, Germany.
Elisabeth MackDepartment of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.ORCID http://orcid.org/0000-0003-4061-494X
Chrysanthi SkevakiInstitute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL), Marburg, Germany.
Christine GaikDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Christian KellerInstitute of Virology, University Hospital Giessen and Marburg, and Philipps University Marburg, Hans-Meerwein-Strasse 2, Marburg, Germany.
Jens FigielDepartment of Diagnostic and Interventional Radiology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Kristina SohlbachDepartment of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Caroline RolfesDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Harald RenzInstitute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL), Marburg, Germany.
Hinnerk WulfDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Andreas BurchertDepartment of Medicine, Hematology, Oncology, Immunology, University Hospital Giessen and Marburg, and Philipps University Marburg, Baldinger Strasse 1, Marburg, Germany.
Universitätsklinikum Gießen und Marburg · DEGerman Center for Lung Research · DEPhilipps University of Marburg · DE
Funding
José Carreras Leukämie-Stiftung (Deutsche José Carreras Leukämie-Stiftung) AH06-01
Abstract
PubMed holds no abstract for this paper.
Indexed as
Coronavirus InfectionsPandemicsPneumonia, ViralRespiratory Distress SyndromeBetacoronavirusCOVID-19HumansJanus Kinase 1NitrilesPyrazolesPyrimidinesSARS-CoV-2Janus Kinase 1NitrilesPyrazolesPyrimidinesruxolitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.